共 162 条
[11]
Douni E(1991)Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis N Engl J Med 325 467-630
[12]
Wajant H(2017)Genetic, immune-inflammatory, and oxidative stress biomarkers as predictors for disability and disease progression in multiple sclerosis Mol Neurobiol 54 31-808
[13]
Probert L(2017)Cytokine profile in patients with progressive multiple sclerosis and its association with disease progression and disability Mol Neurobiol 54 2950-59
[14]
Salomon BL(2014)Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis Expert Opin Drug Metab Toxicol 10 621-1534
[15]
Leclerc M(1998)The soluble 60-kDa tumour necrosis factor receptor: no difference found between patients with relapsing-remitting multiple sclerosis and controls: increasing levels are associated with the recovery from Guillain-Barre syndrome J Neurol 245 803-465
[16]
Tosello J(2014)Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis J Neuroimmunol 271 56-25
[17]
Ronin E(1996)Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 Neurology 47 1531-302
[18]
Piaggio E(1999)TNF neutralization in MS—results of a randomized, placebo controlled multicenter study Neurology 53 457-1452
[19]
Cohen JL(2018)TNFR signaling and its clinical implications Cytokine 101 19-1151
[20]
Arnett HA(2011)Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria Ann Neurol 69 292-50